Dr Reddys Laboratories Ltd Share Price
As on 04 June 2026 at 12:43 IST
Dr Reddy’s Laboratories Q1 FY26 Results:
Profit rose 1% to ₹1,410 crores, compared to ₹1,392 crores in Q1 FY25. Revenue in Q1 FY26 increased 11% to ₹8,545 crores from ₹7,673 crores in the same period last year.
About Dr Reddys Laboratories Ltd
Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has its headquarters in Hyderabad, Telangana, India. Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. The company is committed to making high-quality medicines. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-1.86%
Over 6 Months
-1.36%
Over 1 Year
1.20%
Over 3 Years
37.21%
Dr Reddys Laboratories Ltd Summary
Close ₹1,263.30
Open ₹1,269.50
High ₹1,275.20
Low ₹1,256.90
Volume 12,26,407
Net Turnover (in Cr) ₹155.08
52Wk High ₹1,379.70
52Wk Low ₹1,148.40
52Wk High / Low
1,148.40
1,379.70
Dr Reddys Laboratories Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹1,05,442.22
EPS (TTM) 38.58
Book Value (BV) 375.79
Div. Yield 0.63 %
P/E (TTM) 32.73
Price/Book Value 3.36
Delivery % 56.06 %
Face Value 1
Key Ratios
PE Ratio 17.84
PB Ratio 3.31
EV to Sales 4.24
PEG Ratio -0.24
ROA 16.44
ROE 20.15
Debt-Equity 0.08
Net Profit Margin 23.14
Operating Profit Margin 36.28
Dr Reddys Laboratories Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 33,741.20 | 28,905.40 | 25,725.20 | 22,029.60 | 19,338.90 |
| Total Expenses | 26,083.40 | 21,719.10 | 19,713.70 | 19,038.50 | 16,503.40 |
| Profit Before Tax | 7,679.50 | 7,201 | 6,048.50 | 3,061.40 | 2,883.50 |
| Profit After Tax | 5,725.20 | 5,577.90 | 4,507.30 | 2,182.50 | 1,951.60 |
| Operating Profit After Depreciation | 7,940.70 | 7,357.40 | 6,154.30 | 3,086.90 | 2,932.50 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 18,292.60 | 10,493.90 | 9,274 | 8,135.30 | 8,816.90 |
| Total Non Current Assets | 24,408.50 | 14,058.50 | 11,859.60 | 11,964.60 | 12,066.50 |
| Total Current Assets | 25,018.10 | 24,805.30 | 20,425.50 | 17,782.30 | 14,550.30 |
| Total Assets | 49,426.60 | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 |
| Total Shareholder's Fund | 33,549.60 | 28,254.80 | 23,286.10 | 19,212.40 | 17,641.70 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 4,642.80 | 4,543.30 | 5,887.50 | 2,810.80 | 3,570.30 |
| Net Cash Used In Investing Activities | -5,785.30 | -4,034.20 | -4,108.70 | -2,565.40 | -2,254.70 |
| Net Cash Used In Financing Activities | 1,891.10 | -376.30 | -2,686.10 | -242.20 | -29.80 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 24,118.80 | 20,346.10 | 17,553.80 | 14,887.20 | 14,150.20 |
| Total Expenses | 16,882.90 | 14,554.80 | 13,687.80 | 12,663.40 | 11,094 |
| Profit Before Tax | 7,235.90 | 5,791.30 | 3,866 | 2,223.80 | 3,056.20 |
| Profit After Tax | 5,349.40 | 4,342 | 2,612.80 | 1,623.20 | 2,186.40 |
| Operating Profit After Depreciation | 7,345.80 | 5,813.10 | 3,882.90 | 2,261.80 | 3,102.90 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 8,272.80 | 7,628.20 | 7,220.60 | 6,164.40 | 5,868 |
| Total Non Current Assets | 21,787.90 | 12,543.40 | 11,586.50 | 11,004.30 | 10,685.40 |
| Total Current Assets | 16,503 | 17,815.90 | 13,788.30 | 13,491.30 | 10,944.20 |
| Total Assets | 38,290.90 | 30,359.30 | 25,374.80 | 24,495.60 | 21,629.60 |
| Total Shareholder's Fund | 28,856.60 | 24,240.80 | 20,474.20 | 18,336.20 | 16,983.70 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 4,225 | 3,449.70 | 5,052.90 | 1,338.70 | 3,514.20 |
| Net Cash Used In Investing Activities | -5,697.40 | -3,428.70 | -3,403.20 | -1,990.10 | -1,453.60 |
| Net Cash Used In Financing Activities | 1,590.70 | 68.10 | -2,696.90 | 505.50 | -794.30 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 7,546.40 | 8,753.40 | 8,828.30 | 8,572.10 | 8,528.40 |
| Total Expenses | 7,163.90 | 6,865.90 | 6,818.40 | 6,398.50 | 6,530.50 |
| Profit Before Tax | 199.70 | 1,543.20 | 1,744.80 | 1,905 | 2,005.20 |
| Profit After Tax | 221.30 | 1,189.60 | 1,336.80 | 1,409.90 | 1,586.70 |
| Operating Profit after Depreciation | 862.50 | 2,158.60 | 2,340.10 | 2,464.10 | 2,525.50 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 3,822 | 4,282.70 | 4,618.60 | 7,809.50 | 5,562.90 |
| Total Expenses | 4,321.90 | 4,183.10 | 4,138.30 | 3,972.50 | 4,119.90 |
| Profit Before Tax | -305.50 | 104.20 | 516.30 | 3,936.30 | 1,561.80 |
| Profit After Tax | -219.40 | 90.60 | 387.30 | 2,961.20 | 1,200.70 |
| Operating Profit after Depreciation | 67.30 | 459.90 | 844.50 | 4,235.30 | 1,857.40 |
Dr Reddys Laboratories Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 1,255.07
S2 1,246.83
S3 1,236.77
Pivot 1,265.13
R1 1,273.37
R2 1,283.43
R3 1,291.67
Moving Average
20 SMA 1,304.58
50 SMA 1,278.31
100 SMA 1,265.70
200 SMA 1,262.71
Dr Reddys Laboratories Ltd Corporate Actions
Dr Reddys Laboratories Ltd
₹8.0/Share
Announcement Date 10 Jul 2025
Record Date 10 Jul 2025
Div Yield 800%
Dr Reddys Laboratories Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,789.45 | ₹4,29,349 |
| Divis Laboratories Ltd | ₹6,574.90 | ₹1,74,542.94 |
| Torrent Pharmaceuticals Ltd | ₹4,369.50 | ₹1,47,883.74 |
| Cipla Ltd | ₹1,375.05 | ₹1,11,076.61 |
| Zydus Lifesciences Ltd | ₹1,076.45 | ₹1,08,316.06 |
Dr Reddys Laboratories Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Nippon India Pharma Fund | 7.04% |
| ICICI Pru P.H.D Fund | 5.94% |
| ICICI Pru Value Fund | 2.16% |
| Nippon India Large Cap Fund | 1.37% |
| Parag Parikh Flexi Cap Fund | 1.34% |
Dr Reddys Laboratories Ltd News
Dr Reddys Laboratories Ltd slips for fifth straight session
Dr Reddys Laboratories Ltd is quoting at Rs 1274.9, down 1.2% on the day as on 13:19 IST on the NSE. The stock jumped 2.13% in last one year as compared to a 4.38% slide in NIFTY and a 11.99% spurt in the Nifty Pharma index.
02 Jun 2026, 01:35 pm
Dr. Reddy's launches generic Semaglutide Injection in Canada
16 May 2026, 12:48 pm
Dr Reddys Laboratories Ltd drops for fifth straight session
Dr Reddys Laboratories Ltd is quoting at Rs 1268.7, down 0.1% on the day as on 13:19 IST on the NSE. The stock jumped 3.99% in last one year as compared to a 4.71% slide in NIFTY and a 11.69% spurt in the Nifty Pharma index.
13 May 2026, 01:35 pm
Stock Alert: Dr Reddys Laboratories, Berger Paints, Dixon Tech, Neuland Laboratories, Tata Power
13 May 2026, 08:09 am
Dr Reddys Lab Q4 PAT tumbles 86% YoY to Rs 221 cr
Dr Reddys Laboratories reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.
12 May 2026, 05:34 pm
Dr Reddys Laboratories Ltd Stock Analysis
- Annual revenue for Dr Reddys Laboratories Ltd increased by 18.54% to ₹24,118.80 crore in FY 2025 from ₹20,346.10 crore in FY 2024.
- Annual Net Profit for Dr Reddys Laboratories Ltd increased by 23.20% to ₹5,349.40 crore in FY 2025 from ₹4,342 crore in FY 2024.
- Promoter Shareholding in Dr Reddys Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 26.64% in December 2025 to 26.63% in March 2026.
- Dr Reddys Laboratories Ltd delivered a 1-year return of 1.20% compared to the Nifty 50, which provided a return of -4.63% as of the last trading session.
- Dr Reddys Laboratories Ltd share price moved down by 0.75% from its previous close of INR ₹1,263.30. The latest Dr Reddys Laboratories Ltd share price is INR ₹1,253.80.
- Dr Reddys Laboratories Ltd share price today has been at a low of 1,248.40 and a high of 1,263.20. Over the past 52 weeks, the Dr Reddys Laboratories Ltd share price has seen a low of 1,148.40 and a high of 1,379.70.
About Dr Reddys Laboratories Ltd
Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has grown significantly over the last 40 years. Headquartered in Hyderabad, Telangana, India, Dr. Reddy’s operates worldwide. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products.
Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Among its most recognised products is Omes (omeprazole). It is a medication for gastrointestinal issues.
Although Dr. Reddy’s is not the largest pharmaceutical company, it is highly regarded for its innovative approach. The company continues to grow its influence within the industry by focusing on quality and affordability. The promoters hold approximately 26.65 % of the company’s shares. This reflects its strong commitment to its growth and future direction. Here is a list of its top managing promoters - ‘
The vision of Dr. Reddy’s is to become a leading global pharmaceutical company. Their aim is to provide affordable and innovative medicines for healthier lives. This vision highlights the company’s dedication to addressing unmet medical needs and improving the quality of life for patients all over the world. Dr. Reddy’s does not just focus on expanding its business but aims to make a real impact by ensuring that advanced healthcare solutions reach those who need them most. Dr. Reddy’s wants to bridge the gap between high-quality healthcare solutions and the people who require them. The company strives to meet this vision by offering medicines that are effective, accessible, and affordable.
The company’s mission is clear: to give access to affordable and effective medicines because "good health can’t wait." This simple yet powerful mission statement shows that Dr. Reddy’s knows how crucial it is for patients to get access to good medications. The company places a strong emphasis on improving health outcomes. It is this mission that drives every part of its business—from research and development to marketing and sales.
Innovation lies at the heart of Dr. Reddy’s Laboratories. The company invests heavily in research and development (R&D) to discover new therapies and improve existing ones. It uses cutting-edge technology to stay ahead of the latest scientific advancements. Dr. Reddy’s creates medicines that not only work but are also more accessible to a wider audience.
Making healthcare affordable is a core aspect of Dr. Reddy’s mission. The company is committed to making high-quality medicines available at prices that people can afford. One way Dr. Reddy’s does this is by offering a broad portfolio of generic medicines. These medicines provide cost-effective alternatives to expensive brand-name drugs.
Generics play a crucial role in healthcare systems worldwide by reducing the financial burden on patients. They do this while maintaining the same level of efficacy as their branded counterparts. Through these lower-cost alternatives, Dr. Reddy’s helps make high-quality healthcare more accessible for millions of people across the globe.
Dr. Reddy’s Laboratories is not just focused on India but operates globally. It makes its presence felt in key markets like the United States, Europe and emerging markets across Africa and Latin America. This global reach allows the company to provide much-needed medicines to patients all over the world.
One of the ways Dr. Reddy’s ensures its products are available globally is through partnerships with other organisations. These partnerships help the company tap into new markets and ensure that its medicines are available to people from all walks of life. At the heart of Dr. Reddy’s strategy is a focus on the patient. The company places a strong emphasis on understanding and addressing the needs of its customers. Whether that means improving product quality, speeding up time to market, or providing better service. This patient-centric approach ensures that Dr. Reddy’s delivers solutions that make a difference in the patient’s lives.
Dr. Reddy’s Laboratories Ltd is much more than just a pharmaceutical company. It is a pioneer in making healthcare affordable and accessible to millions of people across the globe. Through its clear vision and mission, the company is driving positive change in the world of healthcare by focusing on innovation, affordability, and sustainability. Through its unwavering focus on making "good health accessible", Dr. Reddy’s Laboratories is truly living up to its mission every day.
Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Among its most recognised products is Omes (omeprazole). It is a medication for gastrointestinal issues.
Although Dr. Reddy’s is not the largest pharmaceutical company, it is highly regarded for its innovative approach. The company continues to grow its influence within the industry by focusing on quality and affordability. The promoters hold approximately 26.65 % of the company’s shares. This reflects its strong commitment to its growth and future direction. Here is a list of its top managing promoters - ‘
- K Satish Reddy
- G V Prasad
- Claudio Albrecht
The objective of Dr. Reddy’s Laboratories Ltd
Dr. Reddy’s Laboratories has a clear vision and mission that guides its actions and decisions. These principles show its commitment to improving global health by enabling access to good medicines.The vision of Dr. Reddy’s is to become a leading global pharmaceutical company. Their aim is to provide affordable and innovative medicines for healthier lives. This vision highlights the company’s dedication to addressing unmet medical needs and improving the quality of life for patients all over the world. Dr. Reddy’s does not just focus on expanding its business but aims to make a real impact by ensuring that advanced healthcare solutions reach those who need them most. Dr. Reddy’s wants to bridge the gap between high-quality healthcare solutions and the people who require them. The company strives to meet this vision by offering medicines that are effective, accessible, and affordable.
The company’s mission is clear: to give access to affordable and effective medicines because "good health can’t wait." This simple yet powerful mission statement shows that Dr. Reddy’s knows how crucial it is for patients to get access to good medications. The company places a strong emphasis on improving health outcomes. It is this mission that drives every part of its business—from research and development to marketing and sales.
Innovation lies at the heart of Dr. Reddy’s Laboratories. The company invests heavily in research and development (R&D) to discover new therapies and improve existing ones. It uses cutting-edge technology to stay ahead of the latest scientific advancements. Dr. Reddy’s creates medicines that not only work but are also more accessible to a wider audience.
Making healthcare affordable is a core aspect of Dr. Reddy’s mission. The company is committed to making high-quality medicines available at prices that people can afford. One way Dr. Reddy’s does this is by offering a broad portfolio of generic medicines. These medicines provide cost-effective alternatives to expensive brand-name drugs.
Generics play a crucial role in healthcare systems worldwide by reducing the financial burden on patients. They do this while maintaining the same level of efficacy as their branded counterparts. Through these lower-cost alternatives, Dr. Reddy’s helps make high-quality healthcare more accessible for millions of people across the globe.
Dr. Reddy’s Laboratories is not just focused on India but operates globally. It makes its presence felt in key markets like the United States, Europe and emerging markets across Africa and Latin America. This global reach allows the company to provide much-needed medicines to patients all over the world.
One of the ways Dr. Reddy’s ensures its products are available globally is through partnerships with other organisations. These partnerships help the company tap into new markets and ensure that its medicines are available to people from all walks of life. At the heart of Dr. Reddy’s strategy is a focus on the patient. The company places a strong emphasis on understanding and addressing the needs of its customers. Whether that means improving product quality, speeding up time to market, or providing better service. This patient-centric approach ensures that Dr. Reddy’s delivers solutions that make a difference in the patient’s lives.
Dr. Reddy’s Laboratories Ltd is much more than just a pharmaceutical company. It is a pioneer in making healthcare affordable and accessible to millions of people across the globe. Through its clear vision and mission, the company is driving positive change in the world of healthcare by focusing on innovation, affordability, and sustainability. Through its unwavering focus on making "good health accessible", Dr. Reddy’s Laboratories is truly living up to its mission every day.
FAQ’s
What is the share price of Dr Reddys Laboratories Ltd today?
Dr Reddys Laboratories Ltd share price as on 4 Jun 2026 is ₹ 1253.8
What is the Market Cap of Dr Reddys Laboratories Ltd?
The market cap of Dr Reddys Laboratories Ltd stock is ₹1,05,442.22 Cr.
What is the PE Ratio of Dr Reddys Laboratories Ltd?
The Price to Earnings (P/E) Ratio of Dr Reddys Laboratories Ltd is 17.84
What is the PB Ratio of Dr Reddys Laboratories Ltd?
The Price to Book (P/B) Ratio of Dr Reddys Laboratories Ltd is 3.31
What is the 52 week high of Dr Reddys Laboratories Ltd Share Price?
The 52 week high of Dr Reddys Laboratories Ltd share price stands at ₹1,379.70
What is the 52 week low of Dr Reddys Laboratories Ltd Share Price?
The 52 week low of Dr Reddys Laboratories Ltd share price stands at ₹1,148.40
How can I buy shares of Dr Reddys Laboratories Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Dr Reddys Laboratories Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
